acta microbiologica hellenica

MDPI

Review

West Nile Virus: Insights into Microbiology, Epidemiology, and Clinical Burden

Andrea Marino [1,*], Ermanno Vitale [2], Antonino Maniaci [2], Luigi La Via [3], Vittoria Moscatt [1], Serena Spampinato [1], Paola Senia [4], Emmanuele Venanzi Rullo [5], Vincenzo Restivo [2], Bruno Cacopardo [1] and Giuseppe Nunnari [1]

[1] Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, ARNAS Garibaldi Hospital, University of Catania, 95122 Catania, Italy; vittoria.moscatt@gmail.com (V.M.); serenaspampinato93@gmail.com (S.S.); cacopard@unict.it (B.C.); giuseppe.nunnari1@unict.it (G.N.)
[2] Department of Medicine and Surgery, University of Enna "Kore", 94100 Enna, Italy; ermanno.vitale@unikore.it (E.V.); tnmaniaci29@gmail.com (A.M.); vincenzo.restivo@unikore.it (V.R.)
[3] Department of Anaesthesia and Intensive Care, University Hospital Policlinico "G. Rodolico-San Marco", 95123 Catania, Italy; luigilavia7@gmail.com
[4] Azienda Provinciale Sanitaria, ASP Catania, 95124 Catania, Italy; paosenia@hotmail.it
[5] Unit of Infectious Diseases, G. Martino University Hospital, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy; emmanuele.venanzirullo@unime.it
* Correspondence: andrea.marino@unict.it

Abstract

West Nile Virus (WNV), a mosquito-borne flavivirus first identified in Uganda in 1937, has emerged over the past quarter century as a major global public health threat. Since its introduction into North America in 1999, WNV has become the leading cause of arboviral neuroinvasive disease, with recurrent outbreaks continuing across Europe, Africa, and the Americas. This review provides a comprehensive overview of the microbiology, epidemiology, and clinical impact of WNV. We discuss the molecular biology of the virus, highlighting its genomic organization, replication strategies, and the structural and non-structural proteins that underpin viral pathogenesis and immune evasion. The complex enzootic transmission cycle, involving Culex mosquitoes and diverse avian reservoir hosts, is examined alongside ecological and climatic determinants of viral amplification and spillover into humans and equines. The clinical spectrum of WNV infection is outlined, ranging from asymptomatic seroconversion to West Nile fever and life-threatening neuroinvasive disease, with particular emphasis on risk factors for severe outcomes in older and immunocompromised individuals. Current approaches to diagnosis, supportive management, and vector control are critically reviewed, while challenges in vaccine development and the absence of effective antiviral therapy are underscored. Finally, we address future research priorities, including therapeutic innovation, predictive outbreak modeling, and genomic surveillance of viral evolution. WNV exemplifies the dynamics of emerging zoonotic diseases, and its persistence underscores the necessity of a coordinated One Health approach integrating human, animal, and environmental health. Continued scientific advances and public health commitment remain essential to mitigate its enduring global impact.

Keywords: West Nile Virus; epidemiology; neuroinvasive disease; vector-borne infections; one health

Academic Editor: Athanasios Tsakris

Received: 29 August 2025
Revised: 1 November 2025
Accepted: 6 November 2025
Published: 8 November 2025

Citation: Marino, A.; Vitale, E.; Maniaci, A.; La Via, L.; Moscatt, V.; Spampinato, S.; Senia, P.; Venanzi Rullo, E.; Restivo, V.; Cacopardo, B.; et al. West Nile Virus: Insights into Microbiology, Epidemiology, and Clinical Burden. *Acta Microbiol. Hell.* **2025**, *70*, 44. https://doi.org/10.3390/amh70040044

1. Introduction

West Nile Virus (WNV), a mosquito-borne neurotropic flavivirus, represents one of the most significant emerging zoonotic pathogens of the last quarter-century [1]. Since its dramatic introduction into the Western Hemisphere in 1999, it has become the leading cause of arboviral neuroinvasive disease in North America and continues to cause sporadic, severe outbreaks globally [2]. The virus's history traces from its initial isolation in the West Nile district of Uganda in 1937, where it was associated with mild febrile illness, to its modern-day status as a cause of potentially fatal meningoencephalitis [3]. This historical arc, marked by a dramatic shift in clinical severity and geographic range, is central to understanding its evolving epidemiology and public health importance.

The global impact of WNV is defined by its vast geographic distribution, spanning all continents except Antarctica, its complex enzootic transmission cycle involving birds and mosquitoes, and the significant morbidity and mortality associated with its neuroinvasive manifestations, particularly in older adults and immunocompromised individuals [3]. The emergence of WNV has placed a substantial burden on public health systems through the costs of patient care, long-term rehabilitation for survivors with neurological deficits, extensive vector control programs, and the implementation of universal screening for the blood and organ supply [4].

The economic impact of WNV is substantial, imposing a heavy burden on healthcare systems and society. Direct costs include hospitalization, long-term care for patients with neurological sequelae, and outpatient visits. Indirect costs, such as lost productivity and disability, further compound the financial strain. For example, major outbreaks have been estimated to cost hundreds of millions of dollars, underscoring the economic rationale for investing in robust surveillance, vector control, and vaccine development programs [5].

This review provides a multi-faceted and comprehensive analysis of West Nile Virus. It begins with an examination of the fundamental virology and molecular biology that govern its replication and pathogenesis. It then explores the intricate epidemiology of the virus, from its natural enzootic cycle to its explosive global expansion and the ecological factors that drive transmission. Finally, it details the full clinical spectrum of WNV disease, from asymptomatic infection to fatal encephalitis, and critically evaluates the current state of diagnosis, clinical management, and public health prevention, including the formidable challenges that remain in the development of effective human vaccines and specific antiviral therapeutics.

2. Virology and Molecular Biology

A thorough understanding of the molecular architecture and replication strategy of West Nile Virus is the key to developing targeted countermeasures. The virus's genetic material, proteins, and life cycle reveal a highly evolved pathogen adept at exploiting host cell machinery in both its invertebrate vectors and vertebrate hosts.

2.1. Taxonomy and Phylogenetics

West Nile Virus is a member of the family *Flaviviridae* and the genus *Orthoflavivirus* [6]. It is classified within the Japanese encephalitis virus (JEV) serocomplex, a group of closely related neurotropic viruses that includes other major human pathogens such as St. Louis encephalitis virus (SLEV), Murray Valley encephalitis virus (MVEV), and JEV itself [3]. This close antigenic relationship is of significant clinical importance, as it leads to serological cross-reactivity that can complicate diagnostic testing [7].

Phylogenetic analysis based on nucleic acid homology has categorized WNV into at least seven, and possibly as many as nine, distinct genetic lineages, with the major lineages diverging by as much as 25–30% at the nucleotide level [8]. Of these, only Lineage

1 and Lineage 2 are consistently implicated in widespread and severe human and equine disease [9].

- **Lineage 1:** This lineage has the broadest global distribution and is historically associated with the most significant outbreaks of neuroinvasive disease. It is found in the Americas, Africa, Europe, Asia, and Australia. Lineage 1 is further divided into sub-lineages; notably, sub-lineage 1a is the strain responsible for the massive epidemic that began in North America in 1999 [10]. Sub-lineage 1b, also known as Kunjin virus, is primarily found in Oceania and is generally associated with a lower incidence of severe neurological symptoms [10].
- **Lineage 2:** This lineage was traditionally endemic to sub-Saharan Africa and Madagascar and was associated with sporadic, milder disease [11]. However, this static view of virulence has been challenged in recent years. Emergent, highly pathogenic strains of Lineage 2 have been responsible for major outbreaks of neuroinvasive disease in Europe, particularly in countries like Greece and Italy, since 2010 [11,12].

The dynamic evolution of WNV virulence illustrates a key principle of RNA virus biology. The inherent plasticity of the viral genome, driven by a high mutation rate, allows for the independent and convergent evolution of virulence-enhancing mutations within different genetic backbones. This means that surveillance programs cannot focus solely on Lineage 1; any WNV lineage circulating in nature possesses the intrinsic potential to acquire mutations that increase its epidemic and pathogenic potential. This reality has profound implications for public health preparedness and vaccine design, mandating that any candidate human vaccine should confer broad, cross-protective immunity against virulent strains from both Lineage 1 and Lineage 2. Encouragingly, studies of E-protein-based vaccine candidates suggest this is an achievable goal [13].

2.2. Virion and Genome Structure

The West Nile virion is a small, spherical particle approximately 45–50 nm in diameter, with an icosahedral nucleocapsid core surrounded by a host-derived lipid envelope [14]. Embedded within this lipid bilayer are the viral structural proteins, the Envelope (E) and Membrane (M) proteins, which form a relatively smooth outer shell [15].

The core of the virion contains the viral genome, a single-stranded, positive-sense RNA molecule (+ssRNA) of approximately 11,000 nucleotides [2]. The genome contains a single long open reading frame (ORF) that is directly translated into a viral polyprotein upon entry into the host cell cytoplasm [2]. The ORF is flanked by highly structured 5′ and 3′ non-coding regions (NCRs) that are indispensable for the viral life cycle [16]. A hallmark of flaviviruses is the absence of a 3′ polyadenylation (poly (A)) tail, which is nearly ubiquitous on eukaryotic mRNAs; instead, the WNV genome terminates in a conserved stem-loop structure ending in a CUOH sequence [2].

Advanced molecular studies have revealed that the WNV genome functions not just as a passive blueprint for proteins but as a highly sophisticated and dynamic RNA machine. The NCRs contain a series of evolutionarily conserved secondary structures, including stem-loops (SLs) and pseudoknots, that act as essential *cis*-acting "riboregulatory elements" [16]. These structures are not merely passive spacers; they are functional components that orchestrate the viral life cycle. Deletion of the terminal SLs at either the 5′ or 3′ end is lethal to the virus, underscoring their critical nature [17,18]. These structures serve as promoters and recognition sites for the viral replication machinery, regulate the switch between translation and replication, and facilitate the long-distance RNA-RNA interactions between the 5′ and 3′ ends. This "genome cyclization" is a physical prerequisite for the initiation of RNA synthesis by the viral polymerase [17–19].

Furthermore, the 3′ NCR contains complex structures, including so-called "dumbbell" repeats and specific SLs, that function to stall host cell 5′-3′ exoribonucleases. This incomplete degradation of the viral genome results in the accumulation of a distinct, non-coding subgenomic flaviviral RNA (sfRNA), which is itself a key molecule for viral pathogenesis and evasion of the host innate immune response [17–19]. The discovery that the genome folds with "minimal host dependence" yet the function of these riboregulatory elements can be "host-specific" provides a profound understanding of viral adaptation [18]. This suggests the virus has evolved a robust, pre-programmed structural scaffold that remains stable across different organisms, while specific elements within this scaffold can be fine-tuned to interact optimally with distinct host factors in vastly different cellular environments, such as a mosquito midgut cell versus a human neuron. This dual functionality of the genome as both an information carrier and a functional machine makes the RNA itself a prime target for novel antiviral strategies, such as those using antisense locked nucleic acids (ASO-LNAs) to physically disrupt these critical structures and inhibit viral growth [18].

2.3. The Viral Proteome

The single ORF of the WNV genome is translated by host ribosomes into a large polyprotein of over 3000 amino acids. This polyprotein is then co- and post-translationally cleaved by a combination of the viral protease complex (NS2B-NS3) and host cell proteases (such as signalase in the ER and furin in the trans-Golgi network) to yield three structural proteins (Capsid [C], pre-Membrane/Membrane [prM/M], and Envelope [E]) and seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [2]. Each of these proteins performs specific and often multiple functions essential for viral replication, assembly, and pathogenesis (See Table 1).

Table 1. Functions of West Nile Virus Proteins.

Protein	Type	Detailed Function(s)
C (Capsid)	Structural	Binds to and packages the viral RNA genome to form the icosahedral nucleocapsid. Also traffics to the nucleus and may play a role in modulating host cell processes, including gene regulation through interactions with histone proteins.
prM/M (pre-Membrane/Membrane)	Structural	The prM protein acts as a critical chaperone for the E protein during virion assembly, stabilizing its conformation and preventing its premature, acid-catalyzed fusion during transport through the exocytic pathway. The final cleavage of the 'pr' peptide from M by host furin in the trans-Golgi network is the essential maturation step that renders the virion infectious.
E (Envelope)	Structural	The primary glycoprotein on the virion surface, arranged as dimers. It mediates viral attachment to host cell receptors (e.g., DC-SIGN, integrins) and, following a low-pH-triggered conformational change in the endosome, drives the fusion of the viral and host membranes. It is the principal target for host-neutralizing antibodies.
NS1	Non-Structural	A highly conserved glycoprotein that exists as a dimer within infected cells and is also secreted as a lipid-associated hexamer. It is an essential cofactor for viral RNA replication, likely by organizing the replication complex. Secreted NS1 can modulate the host complement system and has been implicated in promoting vascular leak and neuroinvasiveness.
NS2A	Non-Structural	A small, multi-pass transmembrane protein with diverse functions in the viral life cycle. It is involved in the assembly of new virions, modulates RNA replication, and is a key antagonist of the host interferon (IFN) signaling pathway.

Table 1. *Cont.*

Protein	Type	Detailed Function(s)
NS2B	Non-Structural	A small integral membrane protein that serves as the essential cofactor for the NS3 protease. It anchors the NS3 protease domain to intracellular membranes, forming the active NS2B-NS3 protease complex required for polyprotein processing.
NS3	Non-Structural	A large, multifunctional enzyme. The N-terminal one-third constitutes a serine protease (in complex with NS2B) that cleaves the viral polyprotein at multiple sites. The C-terminal two-thirds contains RNA helicase and nucleoside triphosphatase (NTPase) activities, which are required to unwind RNA secondary structures during replication.
NS4A	Non-Structural	A small transmembrane protein that functions as a cofactor for the NS3 helicase. It is also responsible for inducing the membrane rearrangements within the host cell that create the replication complexes and has been shown to inhibit IFN signaling.
NS4B	Non-Structural	Another hydrophobic, multi-pass transmembrane protein that is a crucial component of the replication complex. It is also a potent antagonist of the host IFN response, blocking the STAT1 signaling pathway.
NS5	Non-Structural	The largest and most conserved of the flavivirus proteins, possessing two distinct enzymatic domains. The N-terminal domain is a methyltransferase (MTase) responsible for adding a type-1 cap structure to the 5′ end of the viral RNA, which is crucial for translation and evasion of host innate sensing. The C-terminal domain is the RNA-dependent RNA polymerase (RdRp) that catalyzes the synthesis of new viral RNA genomes. NS5 also plays a role in suppressing the IFN response.

2.4. The Viral Replication Cycle

The WNV life cycle is a highly coordinated process that occurs entirely within the cytoplasm of the infected host cell, leveraging host structures and machinery to efficiently produce new viral progeny.

1. **Attachment and Entry:** The cycle initiates when the viral E protein on the virion surface binds to cellular attachment factors, such as glycosaminoglycans, and subsequently to specific entry receptors on the host cell [2]. This interaction triggers internalization of the virus particle via clathrin-mediated endocytosis, enclosing it within an endosome [19].
2. **Fusion and Uncoating:** As the endosome traffics into the cell interior, it undergoes maturation, a process accompanied by a drop in luminal pH from neutral to acidic. This acidic environment induces a dramatic and irreversible conformational rearrangement of the E protein dimers into fusogenic trimers. This change exposes a fusion loop that inserts into the endosomal membrane, driving the fusion of the viral envelope with the endosomal membrane and releasing the nucleocapsid into the cytoplasm. The nucleocapsid then disassembles, uncoating the viral RNA genome [2].
3. **Translation and Polyprotein Processing:** Once free in the cytoplasm, the positive-sense genomic RNA is recognized by host ribosomes and immediately translated. This translation occurs on the surface of the endoplasmic reticulum (ER) and produces the single, large viral polyprotein. As it is being synthesized, the polyprotein is co- and post-translationally cleaved by the viral NS2B-NS3 protease and host proteases to release the ten individual mature structural and non-structural proteins [2].
4. **RNA Replication:** The non-structural proteins induce and associate with invaginations of the ER membrane, forming specialized, vesicle-like structures known as replication complexes or "viral factories" [19]. These structures sequester the components of the replication machinery, concentrating reactants and shielding the viral

RNA from host innate immune sensors. Within these protective vesicles, the NS5 RNA-dependent RNA polymerase (RdRp) uses the input genomic (+ssRNA) as a template to synthesize full-length, complementary negative-sense RNA intermediates (−ssRNA). These −ssRNA intermediates then serve as templates for the asymmetric and massive amplification of new progeny (+ssRNA) genomes [19].

5. **Assembly, Maturation, and Egress:** Newly synthesized (+ssRNA) genomes are encapsidated by the C protein to form nucleocapsids. These nucleocapsids then bud into the lumen of the ER, acquiring a lipid envelope that is studded with the prM and E structural proteins. This process forms immature, non-infectious virions [19,20]. These immature particles are transported through the secretory pathway, moving from the ER to the Golgi apparatus. Within the acidic environment of the trans-Golgi network, the host protease furin cleaves the 'pr' portion of the prM protein. This cleavage is the final and critical maturation step; it causes a structural rearrangement that lays the E proteins flat against the viral surface, stabilizing them in their final, fusion-competent conformation. The now mature, infectious virions are packaged into transport vesicles and released from the cell via exocytosis [14,19].

Notably, while traditionally considered non-infectious, recent evidence indicates that immature virus particles that escape the cell without prM cleavage can still play a role in pathogenesis. These particles can be bound by antibodies against the E or prM proteins, allowing them to infect immune cells via Fc receptor-mediated entry, a process that may contribute to antibody-dependent enhancement (ADE) of infection [21].

3. Epidemiology and Transmission

The epidemiology of West Nile Virus is a compelling narrative of viral evolution, ecological adaptation, and global dispersal. What was once a geographically restricted virus causing mild illness has transformed into a continental pathogen responsible for severe neuroinvasive disease, a shift driven by a complex interplay between the virus, its vectors, its hosts, and the environment.

3.1. Historical Emergence and Global Spread

The recognized history of WNV begins in 1937 with its isolation from the blood of a febrile woman in the West Nile district of Uganda [3] (See Table 2 for Major WNV Outbreaks). For the next several decades, the virus was known to cause infrequent and generally mild febrile outbreaks across Africa, the Middle East, and parts of Southern Europe and Asia [10]. The first well-documented epidemic occurred in Israel in 1951, and subsequent extensive studies in Egypt during the 1950s were pivotal in characterizing its ecology. These studies established its endemicity along the Nile, confirmed its transmission by *Culex* species mosquitoes and identified its broad range of avian reservoir hosts and incidental mammalian hosts, including equines [10]. Throughout this period, WNV was largely considered a pathogen of minor public health importance, primarily causing a self-limiting illness in children [8].

Table 2. Timeline of Major WNV Outbreaks and Geographic Expansion.

Year(s)	Location	Key Features & Significance
1937	West Nile District, Uganda	First isolation of the virus from a human patient with a mild febrile illness.
1950s	Israel, Egypt	First recognized epidemics; detailed characterization of clinical features, endemicity, and the mosquito-bird transmission cycle. Virus considered a minor pathogen.

Table 2. *Cont.*

Year(s)	Location	Key Features & Significance
1996	Bucharest, Romania	Major outbreak with high rates of severe meningoencephalitis, signaling a dramatic shift in the virus's clinical presentation and severity.
1999	New York City, USA	First introduction to the Western Hemisphere. Outbreak of severe neuroinvasive disease and massive associated mortality in native avian species (e.g., crows).
2002–2003	United States (nationwide)	Explosive, coast-to-coast epidemics with 4156 and 9862 cases, respectively, establishing WNV as the dominant arbovirus in the US.
2012	United States (esp. Texas)	Major resurgence in cases (5674 total), with a large outbreak centered in Dallas County, highlighting the continued epidemic potential of the virus in endemic regions.
2010s	Southern/Eastern Europe (e.g., Greece, Italy, Romania)	Recurrent and expanding large outbreaks, driven by emerging virulent Lineage 2 strains, demonstrating ongoing risk and viral evolution in the Old World.
2018	Southern/Central Europe	Unprecedentedly large and geographically widespread outbreak, with a significant number of cases in Italy and the first autochthonous cases reported as far north as Germany. Demonstrated the northward expansion of the virus's range in Europe.
2025	Lazio Region, Italy	A significant summer outbreak of autochthonous WNV neuroinvasive disease, highlighting the persistent endemicity and re-emergence of the virus in previously affected European regions.

A significant shift in the virus's clinical and epidemiological character began in the mid-1990s. An outbreak in Bucharest, Romania, in 1996 was alarming for its unprecedentedly high rate of severe meningoencephalitis and associated mortality, primarily among older adults [10]. This event served as a harbinger of the virus's emerging neurovirulent potential and was followed by similar severe outbreaks in Russia and Israel in the late 1990s [10].

The defining event in the modern history of WNV occurred in the late summer of 1999. An unusual cluster of human encephalitis cases, characterized by profound muscle weakness, was identified by an astute physician in Queens, New York City [19]. Simultaneously, veterinary pathologists at the Bronx Zoo noted extensive die-offs among local bird populations, particularly American Crows [22]. The convergence of these human and animal health investigations led to the stunning identification of West Nile Virus, marking its first-ever appearance in the Western Hemisphere [7]. This introduction, likely via an infected mosquito on an airplane or an infected migratory bird, exposed the profound vulnerability of a technologically advanced nation to the importation of an exotic pathogen [7].

From this initial foothold in New York, the virus disseminated across North America with a speed and scale that stunned the public health world. Facilitated by the movement of infected birds, the virus spread rapidly along migratory flyways. Within just three years, it had reached the Pacific coast, and by 2006, it had been detected in all 48 contiguous U.S. states, southern Canada, Mexico, the Caribbean, and parts of South America [10,14]. The years 2002 and 2003 witnessed massive, nationwide epidemics in the United States, with a cumulative total of over 14,000 reported cases and more than 500 deaths, firmly establishing WNV as the dominant and most important arboviral pathogen in the country [9]. The virus is now considered permanently established and endemic throughout North America [23]. Following its establishment in North America, WNV continued its southward expansion, with detections in Central and South America. Although the region has not experienced

human neuroinvasive disease outbreaks on the scale seen in the United States, the virus has been isolated from mosquitoes, horses, and birds in countries such as Argentina, Brazil, and Colombia [24]. Serological evidence suggests widespread, low-level circulation, but the reasons for the lower incidence of severe human disease remain an area of active investigation, potentially related to cross-protective immunity from other endemic flaviviruses or differences in vector-host dynamics [25].

In the 21st century, Europe has also faced recurrent and expanding WNV outbreaks. An unprecedentedly large outbreak in 2018 affected numerous southern and central European countries, with Italy being particularly hard-hit. This event was notable for the virus's northward expansion, leading to the first locally acquired cases in Germany. More recently, a significant outbreak of neuroinvasive disease in the Lazio region of Italy in the summer of 2025 re-emphasized the virus's firm establishment and ongoing public health threat on the continent [22].

3.2. The Enzootic Transmission Cycle

WNV is maintained and perpetuated in nature through a primary enzootic cycle involving birds as reservoir and amplifying hosts and mosquitoes as biological vectors [19] (Figure 1).



Figure 1. West Nile Virus (WNV) transmission cycle. The virus is maintained in an enzootic cycle (**black double arrow**) between Culex mosquitoes and avian hosts, which act as reservoirs and amplifiers. Some mosquito species function as bridge vectors, transmitting WNV to incidental hosts such as humans and horses (Red arrows), who are considered dead-end hosts because they do not sustain transmission. Environmental factors (temperature, rainfall, and migratory bird movements) strongly influence both vector abundance and viral spread, shaping the intensity and geographic distribution of outbreaks (Green Dashed Arrows).

- **Mosquito Vectors:** Mosquitoes of the genus *Culex* are the principal vectors of WNV globally [2]. In the United States, several species are critical to transmission, with their dominance varying geographically:

Culex pipiens (the northern house mosquito) is a key vector in the eastern and urban areas; *Culex tarsalis* is dominant in the western states; and *Culex quinquefasciatus* (the

southern house mosquito) is important in the Southeast [3]. The ability of a mosquito to transmit the virus, known as vector competence, is a multi-step process. After ingesting a blood meal from a viremic bird, the virus must infect and replicate within the mosquito's midgut epithelial cells, escape into the hemolymph (body cavity), and finally infect the salivary glands. Only when the virus reaches a high titer in the saliva can it be transmitted to a new host during a subsequent blood meal [3]. While some *Culex* species are strongly ornithophilic (preferentially feeding on birds), others are more opportunistic generalists that will also feed on mammals, including humans. These "bridge vectors" [26] are essential for spilling the virus out of its primary avian cycle and into human and equine populations [27]. A seasonal shift in feeding patterns, where mosquitoes switch from avian to mammalian hosts in the late summer, is thought to be a major driver of human outbreaks [28].

- **Avian Reservoir Hosts:** Birds are the cornerstone of the WNV transmission cycle because they serve as amplifying hosts. Following infection, many bird species develop levels of virus in their blood (viremia) that are high enough to infect feeding mosquitoes, thus sustaining and amplifying viral circulation in the environment [2]. While over 320 species of birds in the U.S. have been found to be infected, their roles in the transmission cycle are not equal [29]. Members of the crow family (Corvidae), such as American Crows and Blue Jays, are highly susceptible to WNV, often developing fatal illness. Their deaths serve as a sensitive and highly visible indicator of viral activity, making them valuable sentinels for public health surveillance [22]. However, from a transmission standpoint, species that are highly competent reservoirs—meaning they sustain high viremia but may not die from the infection—are more important for perpetuating the cycle. In much of North America, the American Robin (*Turdus migratorius*) is considered a "super-spreader" and a primary driver of transmission, as it develops high viremia and is a preferred food source for the primary *Culex* vectors [30–32]. The long-distance dispersal of WNV across continents and along major flyways is largely attributed to the movement of infected migratory birds, which introduce the virus into new regions [33–36].

3.3. Epizootic Spillover and Human Infection

Humans and equines are generally considered "dead-end" or incidental hosts for WNV [4]. While they are susceptible to infection and can develop severe disease, the level of viremia they produce is typically too low and transient to efficiently infect a feeding mosquito. This means they do not significantly contribute to the onward transmission of the virus, effectively breaking the cycle [4,37].

While the overwhelming majority of human infections result from the bite of an infected mosquito, several atypical modes of transmission have been identified and are of significant public health concern, even though they account for a very small fraction of cases:

- **Blood Transfusion and Organ Transplantation:** The recognition that WNV could be transmitted via the transplantation of solid organs or the transfusion of blood products from viremic, often asymptomatic, donors was a critical discovery in the early years of the U.S. epidemic. This led to the rapid development and implementation of highly sensitive nucleic acid amplification testing (NAAT) to screen the entire national blood supply. This public health intervention has been remarkably successful, virtually eliminating the risk of transfusion-transmitted WNV [38–40].
- **Perinatal Transmission:** Although extremely rare, cases of vertical transmission from mother to child have been documented, both transplacentally during pregnancy and via breastfeeding after birth [41–43].

- **Occupational Exposure:** Percutaneous exposure through needlesticks or contact with infectious tissues or aerosols in a laboratory setting represents a known risk for researchers and healthcare workers [44].

3.4. Epidemiological Determinants and Risk

The explosive emergence of WNV in North America was not simply a matter of a virus arriving in a new location; it was a "perfect storm" of synergistic factors that created an unprecedented amplification cycle [4,23]. This event was driven by the convergence of a virulent viral strain, a favorable environment, and immunologically naive and highly competent host and vector populations [4,23,45]. The introduction of a highly pathogenic Lineage 1a strain into a temperate climate with abundant urban and rural breeding sites for *Culex* mosquitoes set the stage [27,45]. This environment contained a dense population of avian hosts, such as American Crows and Robins, that were both exquisitely susceptible to infection and capable of generating extremely high viremia, leading to massive viral amplification in the environment [31,46]. This intense transmission pressure among birds, facilitated by widespread and highly competent *Culex* vectors, dramatically increased the frequency of spillover events into the equally naive human population, unmasking the full neuroinvasive potential of the virus on a continental scale [4,23].

Several key factors determine the risk of WNV infection and the likelihood of severe disease:

- **Environmental and Seasonal Factors:** In temperate climates, WNV transmission is strongly seasonal, with the vast majority of human cases occurring in the late summer and early fall (July through September), coinciding with the peak abundance and activity of adult *Culex* mosquitoes [36,47]. Environmental factors such as temperature and rainfall can significantly influence vector populations and viral replication rates [36,48]. Warmer temperatures can shorten the mosquito development cycle and accelerate the extrinsic incubation period (the time it takes for the virus to replicate in the mosquito and reach the salivary glands), thereby increasing transmission efficiency [48]. Geographically, the highest incidence rates in the U.S. are found in the central plains and western states [47].
- **Behavioral and Occupational Factors:** Any activity that increases exposure to mosquito bites elevates the risk of infection. This includes spending significant time outdoors, particularly during the peak biting hours of dusk and dawn [49]. Certain occupations that involve extensive outdoor work, such as agriculture and construction, or direct contact with the virus or its hosts, such as veterinary medicine and laboratory research, have been identified as carrying a higher risk of exposure [44].
- **Host Factors for Severe Disease:** While anyone can become infected, the risk of developing severe neuroinvasive disease is not uniform across the population. The single most important risk factor is advanced age, with individuals over the age of 50, and particularly those over 60, being at the highest risk for WNND and death [50,51].

Immunocompromised status is another major risk factor; solid organ transplant recipients, patients undergoing chemotherapy for cancer, and individuals with other forms of immunosuppression are significantly more likely to develop severe disease [50,51]. Other underlying medical conditions, such as diabetes, hypertension, and kidney disease, have also been associated with an increased risk of severe outcomes [50,51].

Occupational Exposure and Work-Related Risk

Occupational exposure to WNV is an emerging concern, particularly for outdoor workers and professionals with frequent contact with animals or biological samples. Several recent studies have expanded the understanding of work-related risk factors. A systematic

review by Odigie et al. [6] highlighted that military personnel, veterinarians, agricultural workers, farmers, and laboratory staff handling infected materials are among the groups at highest risk of WNV infection, underscoring the importance of tailored preventive measures in occupational health programs.

In Southern Italy, it was reported a measurable seroprevalence of WNV antibodies among outdoor workers, with livestock breeders showing the highest risk (6.5%) [52]. The study also demonstrated that consistent use of repellents and personal protective equipment (PPE) significantly reduced infection risk, supporting the role of behavioral and preventive strategies [52]. Similarly, data from Austria showed a 3.1% seroprevalence of WNV among veterinary practitioners, reinforcing the occupational relevance of this infection in Europe [53].

Broader analyses have emphasized that zoonotic pathogens such as WNV, which can cause severe neurological complications, represent a critical but often underestimated occupational hazard. A One Health-based approach, integrating surveillance across human, animal, and environmental health, is recommended to improve detection and prevention strategies in at-risk sectors [14].

4. Clinical Manifestations and Pathogenesis

Infection with West Nile Virus results in a wide spectrum of clinical outcomes in humans, ranging from completely asymptomatic infection to severe and fatal neurological disease [4,51]. The incubation period following the bite of an infected mosquito typically ranges from 2 to 14 days, though it can be longer in immunocompromised individuals [4,37].

4.1. The Spectrum of Human Disease

The clinical presentation of WNV infection can be broadly categorized into three main outcomes:

- **Asymptomatic Infection:** The vast majority of individuals infected with WNV, estimated at approximately 80%, remain completely asymptomatic [4,49,51]. They develop an immune response and clear the virus without ever knowing they were infected. This high rate of subclinical infection is a major factor in the underreporting of WNV prevalence and underscores the importance of blood supply screening, as asymptomatic donors can be viremic [38].
- **West Nile Fever (WNF):** Approximately 20% of infected people develop a symptomatic, non-neuroinvasive illness known as West Nile Fever [4,50,51]. WNF is typically an acute, self-limiting viral syndrome characterized by the abrupt onset of fever, headache, malaise, myalgia (muscle aches), and profound fatigue [4,50,51]. Gastrointestinal symptoms, including nausea, vomiting, and anorexia, are also frequently reported [4,50,51]. In up to half of WNF cases, patients may develop a transient, non-pruritic maculopapular rash, which characteristically appears on the trunk and extremities as the fever begins to subside [50,51]. While most patients with WNF recover fully within one to two weeks, a significant and often underappreciated aspect of the disease is the potential for prolonged post-viral sequelae. Many individuals, even those with initially "mild" illness, report debilitating fatigue, weakness, and cognitive difficulties (e.g., "brain fog") that can persist for weeks or even months, significantly impacting their quality of life and ability to return to work or daily activities [54]. This represents a substantial hidden burden of WNV-associated morbidity.
- **West Nile Neuroinvasive Disease (WNND):** The most severe manifestation of WNV infection occurs in less than 1% of all infected people (approximately 1 in 150 to 1 in 200 infections) [4,51]. WNND results from the virus crossing the blood–brain barrier and infecting the central nervous system (CNS). It carries a case-fatality rate of

approximately 10% and can result in severe, permanent neurological damage [15,51]. WNND encompasses three distinct clinical syndromes, which can occur alone or in combination:

1. **Meningitis:** This is the least severe form of WNND and involves inflammation of the meninges, the membranes surrounding the brain and spinal cord. Patients present with fever, intense headache, photophobia, and nuchal rigidity (neck stiffness) but typically have a normal level of consciousness [4,51].
2. **Encephalitis:** This is a more severe syndrome involving inflammation of the brain parenchyma itself. It is characterized by signs of cerebral dysfunction, including an altered mental status that can range from confusion, lethargy, and personality changes to deep stupor and coma [4,51,54]. Other common features include tremors (particularly of the limbs and face), seizures, and focal neurological deficits. The development of extrapyramidal signs, such as parkinsonism-like rigidity and bradykinesia, is a characteristic feature of West Nile encephalitis [51,54].
3. **Acute Flaccid Paralysis (AFP):** This is a poliomyelitis-like syndrome caused by WNV-induced damage to the anterior horn cells of the spinal cord. It presents as the acute onset of limb weakness, which is often asymmetric and can progress rapidly over hours to days. In severe cases, it can affect the muscles of respiration, leading to acute respiratory failure that requires prolonged mechanical ventilation [51,55].

Recovery from WNND is often a long and arduous process. A large proportion of survivors are left with persistent or permanent neurological sequelae, including cognitive deficits (memory loss, executive dysfunction), gross and fine motor abnormalities, chronic weakness, and debilitating fatigue [4,54,55].

4.2. Immunopathogenesis

The clinical outcome of a WNV infection is ultimately determined by a complex and delicate balance between the host's immune response and the virus's ability to replicate and cause damage [4,51]. The immune system is essential for controlling and clearing the virus, yet an overly aggressive or dysregulated immune response, particularly within the confined space of the CNS, is a major contributor to the pathology of neuroinvasive disease [20,51,56].

This "double-edged sword" nature of the immune response is central to WNV pathogenesis [20,57]. A robust and rapid peripheral immune response is highly effective at controlling the initial viremia and preventing the virus from ever reaching the CNS [4,58]. However, should the virus successfully breach the blood–brain barrier and establish an infection in the brain or spinal cord, the subsequent neuroinflammatory response becomes both protective and pathogenic [20,59,60]. The infiltration of immune cells, such as T-lymphocytes and macrophages, into the CNS is necessary to clear infected neurons and limit viral spread [56,58,59]. However, the release of pro-inflammatory cytokines and chemokines by these cells can lead to significant bystander damage, disrupting the blood–brain barrier, causing cerebral edema, and contributing directly to neuronal death [57,59,60]. Thus, the severity of WNND is a function of both direct viral-mediated cytopathology and indirect, immune-mediated injury [20,51,56].

- **Host Immune Control:** The host employs a multi-layered defense against WNV.
    - **Innate Immunity:** Type I interferons (IFN-α/β) represent the critical first line of defense. They are induced upon cellular recognition of viral RNA and establish

an antiviral state in surrounding cells, which is essential for restricting initial viral replication and limiting dissemination to the CNS [58,61,62].

- **Humoral Immunity:** B-cell-produced antibodies, particularly neutralizing antibodies that target the viral E protein, are crucial for clearing free virus from the bloodstream (viremia) and preventing cell-to-cell spread [63,64]. The generation of a strong neutralizing antibody response is the primary goal of vaccination and the basis for experimental passive antibody therapies [64,65].
- **Cell-Mediated Immunity:** Cytotoxic T-lymphocytes (CTLs) are essential for recognizing and eliminating virus-infected cells, a role that is particularly critical for clearing an established infection within the CNS [56,59,66].

- **Viral Evasion Strategies:** To succeed, WNV must counteract these host defenses. The virus has evolved specific countermeasures, primarily mediated by its non-structural proteins. Several NS proteins, including NS1, NS2A, NS4B, and NS5, have been shown to be potent antagonists of the host interferon signaling pathway [61,67,68]. They act at various points in the pathway to block IFN production or the downstream signaling cascade, thereby delaying the establishment of an antiviral state and giving the virus a crucial head start to replicate before the host immune response can be fully mobilized [67–69].

5. Diagnosis, Management, and Prevention

Given the potential for severe outcomes, the accurate diagnosis, supportive management, and robust prevention of West Nile Virus infection are pillars of the public health response [4,51]. While significant advances have been made in diagnostics and prevention, the lack of a specific antiviral therapy remains a critical gap [51,70].

5.1. Laboratory Diagnosis

The definitive diagnosis of WNV infection relies on laboratory testing, as the clinical symptoms are non-specific and can overlap with many other viral illnesses [4,9]. The primary diagnostic approach involves serological testing for WNV-specific antibodies, supplemented by molecular methods in specific clinical contexts [4,71]. See Table 3.

Table 3. Diagnostic Testing for West Nile Virus.

Test	Specimen(s)	Optimal Timing	Interpretation & Key Considerations
IgM Antibody ELISA	Serum, CSF	3–8 days post-onset	**Primary screening test.** A positive result indicates recent infection. Can persist for months. A negative result early in illness does not rule out WNV. Subject to cross-reactivity with other flaviviruses.
IgG Antibody ELISA	Serum	>7 days post-onset	Indicates past infection. Persists for years. Not useful for diagnosing acute disease alone.
RT-qPCR	CSF, Serum, Urine, Whole Blood, Tissue	<7 days post-onset (ideally <3–5 days)	**Detects viral RNA**. Primary method for early, acute diagnosis. Preferred for immunocompromised patients and for testing CSF. Urine can remain positive for longer periods. Low sensitivity in serum of immunocompetent patients after symptom onset.
Plaque Reduction Neutralization Test (PRNT)	Serum (paired acute & convalescent samples)	Acute: <14 days; Convalescent: 2–3 weeks later	**Gold standard for confirmation.** Differentiates between cross-reacting flaviviruses. A ≥4-fold rise in neutralizing antibody titer confirms acute infection. Performed at public health labs.
Immunohistochemistry (IHC)	Formalin-fixed tissue (autopsy)	Post-mortem	Detects WNV antigen in tissue. Used to confirm diagnosis in fatal cases and to study tissue tropism.

- **Serological Testing:** The detection of WNV-specific Immunoglobulin M (IgM) antibodies in a patient's serum or cerebrospinal fluid (CSF) is the most common method for diagnosing an acute infection [4,71,72]. WNV-specific IgM antibodies are typically detectable by ELISA 3 to 8 days after the onset of symptoms and can persist for 30 to 90 days, or occasionally longer [71–73]. Therefore, a positive IgM result provides strong evidence of a recent infection. However, if a sample is collected very early in the course of illness (within the first 8 days), an initial IgM test may be negative, and a repeat test on a convalescent sample may be necessary to confirm the diagnosis [72]. The detection of WNV-specific IgG antibodies, which appear shortly after IgM and can persist for years, indicates a past infection and is not useful for diagnosing acute disease on its own [4,72,73].
- **The Challenge of Cross-Reactivity and Confirmatory Testing:** A major limitation of flavivirus serology is the potential for antibody cross-reactivity [9,73]. Because of the structural similarities among viruses in the JEV serocomplex (like WNV and SLEV) and other co-circulating flaviviruses (like Dengue or Zika virus), an initial positive IgM ELISA result may not be specific to WNV [74]. For this reason, confirmatory testing with the Plaque Reduction Neutralization Test (PRNT) is often required [74]. The PRNT is the gold standard for flavivirus serology; it measures the titer of virus-specific neutralizing antibodies and can reliably differentiate the causative agent [45,75]. A fourfold or greater increase in the neutralizing antibody titer between acute- and convalescent-phase serum samples, collected 2 to 3 weeks apart, provides definitive confirmation of an acute WNV infection [45,75].
- **Molecular Testing:** Molecular testing using Reverse Transcription-Polymerase Chain Reaction (RT-PCR), particularly real-time RT-PCR (RT-qPCR), is the cornerstone for diagnosis in the early, acute phase of illness, before a robust antibody response has developed [9,45]. While viremia in immunocompetent patients is often transient, making serum a challenging sample [76,77]. RT-PCR remains the preferred method for testing cerebrospinal fluid (CSF) in patients with suspected neuroinvasive disease and for diagnosing immunocompromised patients, who may have prolonged viremia and an attenuated antibody response [45,78]. Furthermore, viral RNA can be detected in urine for longer periods than in blood, sometimes beyond 7 days post-symptom onset, making it a valuable non-invasive specimen for diagnosis [78]. Studies also suggest that whole blood may be a more sensitive specimen than serum for WNV RNA detection [77].

5.2. Clinical Management and Treatment

There is currently no specific antiviral medication approved for the treatment of West Nile Virus disease. Clinical management is, therefore, entirely supportive, focusing on alleviating symptoms and managing complications [4,14,51].

- **Management of West Nile Fever:** For patients with the milder, non-neuroinvasive form of the disease, treatment is symptomatic. This includes rest, ensuring adequate fluid intake to prevent dehydration, and the use of over-the-counter analgesics (e.g., acetaminophen) for fever and myalgia, and antiemetics for nausea and vomiting [4,71].
- **Management of West Nile Neuroinvasive Disease:** Patients with WNND require hospitalization for close monitoring and intensive supportive care [4,14,51]. Management strategies may include intravenous fluids to maintain hydration and electrolyte balance, aggressive pain control for severe headaches, and anti-seizure medications if convulsions occur [4,79]. For patients with severe encephalitis or AFP leading to an inability to protect their airway or progressing to respiratory failure, critical

care support with endotracheal intubation and mechanical ventilation may be life-saving [51,79]. Over the past two decades, various experimental therapeutics have been investigated for WNV disease, but none have demonstrated clear efficacy in well-controlled, randomized clinical trials [14,70].

- **Polyclonal Intravenous Immune Globulin (IVIG):** Case reports and small case series, particularly in immunocompromised patients, have shown variable and inconclusive results, with no clear evidence of improved survival or neurological outcomes [80–82].
- **Interferon:** While interferon-α-2b shows antiviral activity against WNV in vitro, clinical studies have been small and unblinded, yielding equivocal results and concerns about side effects [70,83].
- **Ribavirin:** This broad-spectrum antiviral has been used, but observational data failed to show a benefit and suggested it might be associated with worse outcomes, likely due to confounding by indication (i.e., it was given to the sickest patients) [70,84,85].
- **Corticosteroids:** The use of steroids to quell the neuroinflammatory response is controversial [86]. A systematic review found no evidence of benefit for viral encephalitis, and their use in WNV remains off-label and without robust supporting data [87–89].
- **Monoclonal Antibodies:** A high-affinity humanized monoclonal antibody (MGAWN1) targeting the WNV E protein showed promise in preclinical studies [64]. However, a Phase 1/2 clinical trial was terminated early due to difficulty with enrolment, highlighting the logistical challenges of studying therapies for a sporadic, seasonal disease [90].

5.3. Prevention and Public Health Control

In the absence of a human vaccine or specific treatment, the entire strategy for combating WNV rests on preventing transmission at the human–vector–animal interface [37,91]. This requires a comprehensive "One Health" approach that integrates human, animal, and environmental health interventions [92]. Effective control is impossible without coordinating surveillance of the virus in its animal reservoirs and vectors with targeted control measures and public education [93].

- **Integrated Mosquito Management (IMM):** This is the cornerstone of community-level prevention and aims to reduce vector populations [94].
    - **Surveillance:** The foundation of any IMM program is robust surveillance. This involves trapping adult mosquitoes to monitor species abundance and test for WNV infection, as well as monitoring sentinel animal populations, such as chickens or dead birds, to provide an early warning of viral activity in a given area [9,95]. This data is crucial for guiding the timing and location of control measures.
    - **Source Reduction:** The most effective and sustainable long-term strategy is eliminating mosquito breeding sites. This primarily involves public education campaigns that empower residents to remove sources of standing water on their property, such as in discarded tires, buckets, planters, and clogged rain gutters, where *Culex* mosquitoes lay their eggs [94,96].
    - **Larviciding and Adulticiding:** When surveillance indicates a high risk to human health, chemical control methods are employed. Larvicides are applied to standing water bodies that cannot be drained to kill mosquito larvae before they emerge as adults [27]. Adulticiding, or "fogging," which involves the ground or aerial spraying of insecticides, is used as a reactive measure to rapidly reduce the population of infected adult mosquitoes during an outbreak [27,97].

- **Personal Protective Measures:** Individual behavior is a critical component of prevention [98]. Public health messaging focuses on:
    - **Using Insect Repellent:** Consistent use of EPA-registered repellents containing active ingredients such as DEET, picaridin, or oil of lemon eucalyptus on exposed skin is highly effective [98–100].
    - **Wearing Protective Clothing:** Long-sleeved shirts and long pants can minimize exposed skin available for mosquito bites [98].
    - **Avoiding Peak Biting Times:** Limiting outdoor activity during the hours of dusk and dawn, when *Culex* mosquitoes are most active, can reduce exposure [43].
    - **Using Screens:** Ensuring that windows and doors on homes have intact screens to keep mosquitoes out [43].
- **Blood and Organ Supply Safety:** To prevent iatrogenic transmission, all blood donations in the United States are screened for WNV RNA using NAAT, a public health success that has virtually eliminated this transmission route. Similar strategies have been adopted across Europe, tailored to local epidemiological risk. For instance, France has implemented a comprehensive strategy that includes systematic screening in high-risk areas during transmission seasons and deferral criteria for donors returning from endemic zones to safeguard both solid organ and hematopoietic stem cell grafts [40,101,102]. Furthermore, individuals with a confirmed WNV infection are deferred from donating blood for 120 days (4 months) following their illness [101].

One Health Approach

A coordinated One Health approach is particularly critical in regions like the Mediterranean basin, where the virus is endemic [14]. Integrated surveillance systems that monitor WNV in mosquitoes, wild birds, equines, and humans have been developed to provide early warnings of viral circulation and guide targeted public health interventions [12]. This regional strategy, which combines veterinary, entomological, and human health data, is essential for mitigating WNV risk in an area with complex ecological and climatic drivers of transmission [6,103].

6. Future Directions and Conclusion

More than two decades after its dramatic arrival in the Americas, West Nile Virus remains a significant and persistent public health threat [23,104]. While the scientific community has made remarkable progress in understanding its biology and epidemiology, critical gaps in our ability to treat and vaccinate against the disease persist, defining the major challenges for the future [13].

6.1. Vaccine Development: The Unfinished Race

The development of a safe and effective human vaccine against WNV is a paramount public health goal, particularly for protecting the elderly and other vulnerable populations from severe neuroinvasive disease [105]. The existence of four licensed and effective veterinary vaccines for horses clearly demonstrates that vaccine-mediated protection against WNV is an achievable objective [106].

A variety of vaccine platforms have been advanced into human clinical trials, including DNA vaccines, inactivated whole-virus vaccines, and chimeric live-attenuated viruses such as ChimeriVax-WNV, which uses the yellow fever 17D vaccine backbone [107,108]. These candidates have generally demonstrated good safety profiles and the ability to elicit robust neutralizing antibody responses in early-phase trials [107,109]. The recent launch of a new

Phase 1 trial for a second-generation inactivated WNV vaccine shows that research and development efforts are ongoing [110].

Despite this progress, no human WNV vaccine has successfully navigated the path to licensure. The reasons for this are not a failure of basic science but rather a formidable triad of interconnected logistical, economic, and regulatory barriers [111].

1. **The Epidemiological/Logistical Barrier:** WNV outbreaks are sporadic, seasonal, and unpredictable in their geographic location and intensity from year to year. This epidemiological pattern makes it extraordinarily difficult and expensive to plan and execute traditional, large-scale Phase III efficacy trials, which require enrolling thousands of participants in a region where a significant outbreak is guaranteed to occur to demonstrate a statistically significant reduction in disease [112,113].
2. **The Economic Barrier:** The primary target population for a WNV vaccine is older adults. From a commercial standpoint, the high cost of conducting large-scale Phase III efficacy trials is difficult to justify for a disease with a sporadic and unpredictable incidence, creating a challenging economic model for pharmaceutical investment and dampening commercial interest in late-stage development [5,114].
3. **The Scientific/Regulatory Barrier:** A major safety concern for any flavivirus vaccine is the theoretical risk of antibody-dependent enhancement (ADE). This phenomenon, best described for dengue virus, occurs when non-neutralizing or sub-neutralizing antibodies from a previous infection or vaccination bind to a different flavivirus and enhance its uptake into immune cells, potentially leading to a more severe infection [115]. Given the increasing co-circulation of WNV with other flaviviruses like Zika and St. Louis encephalitis virus, the potential for vaccine-induced antibodies to worsen a subsequent infection raises the safety bar for regulatory approval significantly [92,116].

Overcoming these hurdles will require more than just a promising vaccine molecule. It will necessitate innovative approaches to clinical trial design (e.g., using immunobridging or controlled human infection models) [117], new public–private partnership models to de-risk the economic investment for "outbreak" vaccines, and sophisticated vaccine engineering to focus the immune response on highly specific, non-cross-reactive epitopes to minimize the theoretical risk of ADE [116,118].

6.2. Unanswered Questions and Research Priorities

While much has been learned, key questions remain that must be addressed to improve the response to WNV [4,37].

- **Therapeutics:** The development of a potent, specific, and orally bioavailable antiviral drug for WNV remains a top priority [119,120]. Targeting the essential viral enzymes, such as the NS3 protease/helicase or the NS5 polymerase, or pursuing novel strategies that target the functional RNA structures of the viral genome, are promising avenues for future research [121–123].
- **Predictive Modeling:** Enhancing the accuracy of epidemiological models to forecast the time, location, and intensity of future outbreaks is critical [124,125]. Integrating climate data, vector surveillance, avian host data, and human case data into sophisticated predictive models could allow public health officials to deploy limited resources for vector control and public education more efficiently and proactively [124,126,127].
- **Pathogenesis:** A deeper understanding of the molecular mechanisms of viral neuroinvasion and the specific host factors that determine why one individual remains asymptomatic while another develops fatal encephalitis is urgently needed [20,128]. Elucidating the biological basis of the long-term cognitive and physical sequelae that afflict many survivors is also a critical area for future study [128–130].

- **Ecology and Evolution:** Continuous genomic surveillance of WNV strains circulating in nature is essential to monitor for the emergence of new, more virulent mutations or shifts in lineage distribution [131,132] Likewise, ongoing research into vector-host dynamics is necessary to understand how factors like climate change and land use may alter transmission patterns in the future [133–135].

7. Conclusions

West Nile Virus has unequivocally established itself as a permanent and formidable public health challenge in the 21st century. Its remarkable journey from a relatively obscure African virus to a major cause of neuroinvasive disease across multiple continents serves as a stark and compelling lesson in the dynamics of emerging and re-emerging infectious diseases. The global scientific and public health communities have made enormous strides in dissecting its molecular biology, unraveling its complex transmission cycle, and characterizing its clinical impact.

However, this wealth of knowledge has yet to translate into the tools most needed to protect human populations: a specific antiviral therapy and a licensed human vaccine. Moving forward, mitigating the ongoing threat of WNV will depend on a sustained commitment to the "One Health" paradigm, strengthening the integration of human, veterinary, and environmental surveillance and control efforts. The ultimate conquest of West Nile Virus will require not only continued scientific innovation but also new and creative paradigms in public health policy, clinical trial execution, and economic investment to finally bridge the persistent and challenging gap between promising research and licensed medical countermeasures.

Author Contributions: Conceptualization, A.M. (Andrea Marino) and E.V.; methodology, A.M. (Antonino Maniaci) and L.L.V.; investigation, V.M.; writing—original draft preparation, S.S. and P.S.; writing—review and editing, V.M., S.S., P.S. and A.M. (Andrea Marino); supervision, V.R., B.C., E.V.R. and G.N. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Saydam, F.N.; Erdem, H.; Ankarali, H.; El-Arab Ramadan, M.E.; El-Sayed, N.M.; Civljak, R.; Pshenichnaya, N.; Moroti, R.V.; Mahmuodabad, F.M.; Maduka, A.V.; et al. Vector-Borne and Zoonotic Infections and Their Relationships with Regional and Socioeconomic Statuses: An ID-IRI Survey in 24 Countries of Europe, Africa and Asia. *Travel. Med. Infect. Dis.* **2021**, *44*, 102174. [CrossRef] [PubMed]
2. Brinton, M.A. The Molecular Biology of West Nile Virus: A New Invader of the Western Hemisphere. *Annu. Rev. Microbiol.* **2002**, *56*, 371–402. [CrossRef]
3. Hayes, E.B.; Komar, N.; Nasci, R.S.; Montgomery, S.P.; O'Leary, D.R.; Campbell, G.L. Epidemiology and Transmission Dynamics of West Nile Virus Disease. *Emerg. Infect. Dis.* **2005**, *11*, 1167–1173. [CrossRef]
4. Petersen, L.R.; Brault, A.C.; Nasci, R.S. West Nile Virus: Review of the Literature. *JAMA* **2013**, *310*, 308–315. [CrossRef]
5. Barrett, A.D.T. Economic Burden of West Nile Virus in the United States. *Am. J. Trop. Med. Hyg.* **2014**, *90*, 389–390. [CrossRef]
6. Odigie, A.E.; Stufano, A.; Schino, V.; Zarea, A.A.K.; Ndiana, L.A.; Mrenoshki, D.; Ugochukwu, I.C.I.; Lovreglio, P.; Greco, G.; Pratelli, A.; et al. West Nile Virus Infection in Occupational Settings—A Systematic Review. *Pathogens* **2024**, *13*, 157. [CrossRef]
7. Asnis, D.S.; Conetta, R.; Teixeira, A.A.; Waldman, G.; Sampson, B.A. The West Nile Virus Outbreak of 1999 in New York: The Flushing Hospital Experience. *Clin. Infect. Dis.* **2000**, *30*, 413–418. [CrossRef]

8. Colpitts, T.M.; Conway, M.J.; Montgomery, R.R.; Fikrig, E. West Nile Virus: Biology, Transmission, and Human Infection. *Clin. Microbiol. Rev.* **2012**, *25*, 635–648. [CrossRef] [PubMed]
9. CDC West Nile Virus. Available online: https://www.cdc.gov/west-nile-virus/index.html (accessed on 12 August 2025).
10. Hubálek, Z.; Halouzka, J. West Nile Fever–a Reemerging Mosquito-Borne Viral Disease in Europe. *Emerg. Infect. Dis.* **1999**, *5*, 643–650. [CrossRef]
11. Visser, I.; Marshall, E.M.; Agliani, G.; Rissmann, M.; van den Brand, J.M.A.; Koopmans, M.P.G.; Rockx, B. In Vitro and In Vivo Characterization of a Novel West Nile Virus Lineage 2 Strain. *NPJ Viruses* **2024**, *2*, 61. [CrossRef]
12. Koch, R.T.; Erazo, D.; Folly, A.J.; Johnson, N.; Dellicour, S.; Grubaugh, N.D.; Vogels, C.B.F. Genomic Epidemiology of West Nile Virus in Europe. *One Health* **2024**, *18*, 100664. [CrossRef] [PubMed]
13. Ulbert, S. West Nile Virus Vaccines—Current Situation and Future Directions. *Hum. Vaccin. Immunother.* **2019**, *15*, 2337–2342. [CrossRef]
14. Habarugira, G.; Suen, W.W.; Hobson-Peters, J.; Hall, R.A.; Bielefeldt-Ohmann, H. West Nile Virus: An Update on Pathobiology, Epidemiology, Diagnostics, Control and "One Health" Implications. *Pathogens* **2020**, *9*, 589. [CrossRef]
15. Gould, C.V.; Staples, J.E.; Guagliardo, S.A.J.; Martin, S.W.; Lyons, S.; Hills, S.L.; Nett, R.J.; Petersen, L.R. West Nile Virus: A Review. *JAMA* **2025**, *334*, 618. [CrossRef]
16. Bignon, E.; Marazzi, M.; Miclot, T.; Barone, G.; Monari, A. Specific Recognition of the 5′-Untranslated Region of West Nile Virus Genome by Human Innate Immune System. *Viruses* **2022**, *14*, 1282. [CrossRef]
17. Terrell, J.R.; Le, T.T.; Paul, A.; Brinton, M.A.; Wilson, W.D.; Poon, G.M.K.; Germann, M.W.; Siemer, J.L. Structure of an RNA G-Quadruplex from the West Nile Virus Genome. *Nat. Commun.* **2024**, *15*, 5428. [CrossRef] [PubMed]
18. Huston, N.C.; Tsao, L.H.; Brackney, D.E.; Pyle, A.M. The West Nile Virus Genome Harbors Essential Riboregulatory Elements with Conserved and Host-Specific Functional Roles. *Proc. Natl. Acad. Sci. USA* **2024**, *121*, e2312080121. [CrossRef]
19. Brinton, M.A. Replication Cycle and Molecular Biology of the West Nile Virus. *Viruses* **2013**, *6*, 13–53. [CrossRef]
20. Suthar, M.S.; Diamond, M.S.; Gale, M. West Nile Virus Infection and Immunity. *Nat. Rev. Microbiol.* **2013**, *11*, 115–128. [CrossRef]
21. Seregin, A.; Nistler, R.; Borisevich, V.; Yamshchikov, G.; Chaporgina, E.; Kwok, C.W.; Yamshchikov, V. Immunogenicity of West Nile Virus Infectious DNA and Its Noninfectious Derivatives. *Virology* **2006**, *356*, 115–125. [CrossRef] [PubMed]
22. Weekly Updates: 2025 West Nile Virus Transmission Season. Available online: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc (accessed on 12 August 2025).
23. Kramer, L.D.; Styer, L.M.; Ebel, G.D. A Global Perspective on the Epidemiology of West Nile Virus. *Annu. Rev. Entomol.* **2008**, *53*, 61–81. [CrossRef] [PubMed]
24. Matta, N.E.; Gaitán-Albarracín, F.A.; Fuentes-Rodríguez, G.A.; Rodríguez-Fandiño, Ó.A.; Calixto-Botía, I.F.; Correa-Higuera, L.J. Survey of West Nile Virus Infection in Wildlife Species in the Orinoquia Region of Colombia. *Front. Microbiol.* **2025**, *16*, 1548538. [CrossRef] [PubMed]
25. Lorenz, C.; Chiaravalloti-Neto, F. Why Are There No Human West Nile Virus Outbreaks in South America? *Lancet Reg. Health–Am.* **2022**, *12*, 100276. [CrossRef]
26. CDC Transmission of West Nile Virus. Available online: https://www.cdc.gov/west-nile-virus/php/transmission/index.html (accessed on 1 November 2025).
27. Turell, M.J.; Dohm, D.J.; Sardelis, M.R.; O'guinn, M.L.; Andreadis, T.G.; Blow, J.A. An Update on the Potential of North American Mosquitoes (Diptera: Culicidae) to Transmit West Nile Virus. *J. Med. Entomol.* **2005**, *42*, 57–62. [CrossRef]
28. Kilpatrick, A.M.; Meola, M.A.; Moudy, R.M.; Kramer, L.D. Temperature, Viral Genetics, and the Transmission of West Nile Virus by Culex Pipiens Mosquitoes. *PLoS Pathog.* **2008**, *4*, e1000092. [CrossRef]
29. Where in the United States Has West Nile Virus Been Detected in Wildlife? | U.S. Geological Survey. Available online: https://www.usgs.gov/faqs/where-united-states-has-west-nile-virus-been-detected-wildlife (accessed on 12 August 2025).
30. Riccetti, N.; Fasano, A.; Ferraccioli, F.; Gomez-Ramirez, J.; Stilianakis, N.I. Host Selection and Forage Ratio in West Nile Virus-Transmitting Culex Mosquitoes: Challenges and Knowledge Gaps. *PLoS Negl. Trop. Dis.* **2022**, *16*, e0010819. [CrossRef]
31. Vaughan, J.A.; Newman, R.A.; Turell, M.J. Bird Species Define the Relationship between West Nile Viremia and Infectiousness to Culex Pipiens Mosquitoes. *PLoS Negl. Trop. Dis.* **2022**, *16*, e0010835. [CrossRef] [PubMed]
32. Jahn, A.E.; Koller, K.; Martin, L.B.; Smiley, T.M.; Verrett, T.B.; Ketterson, E.D.; Williams, E.J.; Becker, D.J. Movement-Related Drivers of Exposure to West Nile Virus by American Robins (Turdus migratorius). *bioRxiv* **2023**. [CrossRef]
33. Owen, J.; Moore, F.; Panella, N.; Edwards, E.; Bru, R.; Hughes, M.; Komar, N. Migrating Birds as Dispersal Vehicles for West Nile Virus. *EcoHealth* **2006**, *3*, 79–85. [CrossRef]
34. Swetnam, D.; Widen, S.G.; Wood, T.G.; Reyna, M.; Wilkerson, L.; Debboun, M.; Symonds, D.A.; Mead, D.G.; Beaty, B.J.; Guzman, H.; et al. Terrestrial Bird Migration and West Nile Virus Circulation, United States. *Emerg. Infect. Dis.* **2018**, *24*, 2184–2194. [CrossRef]
35. Moon, S.A.; Cohnstaedt, L.W.; McVey, D.S.; Scoglio, C.M. A Spatio-Temporal Individual-Based Network Framework for West Nile Virus in the USA: Spreading Pattern of West Nile Virus. *PLoS Comput. Biol.* **2019**, *15*, e1006875. [CrossRef]

36. Reisen, W.K.; Wheeler, S.S.; Garcia, S.; Fang, Y. Migratory Birds and the Dispersal of Arboviruses in California. *Am. J. Trop. Med. Hyg.* **2010**, *83*, 808–815. [CrossRef]
37. Chancey, C.; Grinev, A.; Volkova, E.; Rios, M. The Global Ecology and Epidemiology of West Nile Virus. *Biomed. Res. Int.* **2015**, *2015*, 376230. [CrossRef]
38. Pealer, L.N.; Marfin, A.A.; Petersen, L.R.; Lanciotti, R.S.; Page, P.L.; Stramer, S.L.; Stobierski, M.G.; Signs, K.; Newman, B.; Kapoor, H.; et al. Transmission of West Nile Virus through Blood Transfusion in the United States in 2002. *N. Engl. J. Med.* **2003**, *349*, 1236–1245. [CrossRef]
39. Iwamoto, M.; Jernigan, D.B.; Guasch, A.; Trepka, M.J.; Blackmore, C.G.; Hellinger, W.C.; Pham, S.M.; Zaki, S.; Lanciotti, R.S.; Lance-Parker, S.E.; et al. Transmission of West Nile Virus from an Organ Donor to Four Transplant Recipients. *N. Engl. J. Med.* **2003**, *348*, 2196–2203. [CrossRef]
40. Stramer, S.L.; Fang, C.T.; Foster, G.A.; Wagner, A.G.; Brodsky, J.P.; Dodd, R.Y. West Nile Virus among Blood Donors in the United States, 2003 and 2004. *N. Engl. J. Med.* **2005**, *353*, 451–459. [CrossRef]
41. Alpert, S.G.; Fergerson, J.; Noël, L.P. Intrauterine West Nile Virus: Ocular and Systemic Findings. *Am. J. Ophthalmol.* **2003**, *136*, 733–735. [CrossRef]
42. Hinckley, A.F.; O'Leary, D.R.; Hayes, E.B. Transmission of West Nile Virus through Human Breast Milk Seems to Be Rare. *Pediatrics* **2007**, *119*, e666–e671. [CrossRef] [PubMed]
43. Skupski, D.W.; Eglinton, G.S.; Fine, A.D.; Hayes, E.B.; O'Leary, D.R. West Nile Virus during Pregnancy: A Case Study of Early Second Trimester Maternal Infection. *Fetal Diagn. Ther.* **2006**, *21*, 293–295. [CrossRef] [PubMed]
44. Centers for Disease Control and Prevention (CDC) Laboratory-Acquired West Nile Virus Infections—United States, 2002. *MMWR Morb. Mortal. Wkly. Rep.* **2002**, *51*, 1133–1135.
45. Lanciotti, R.S.; Kerst, A.J.; Nasci, R.S.; Godsey, M.S.; Mitchell, C.J.; Savage, H.M.; Komar, N.; Panella, N.A.; Allen, B.C.; Volpe, K.E.; et al. Rapid Detection of West Nile Virus from Human Clinical Specimens, Field-Collected Mosquitoes, and Avian Samples by a TaqMan Reverse Transcriptase-PCR Assay. *J. Clin. Microbiol.* **2000**, *38*, 4066–4071. [CrossRef] [PubMed]
46. Komar, N.; Langevin, S.; Hinten, S.; Nemeth, N.M.; Edwards, E.; Hettler, D.L.; Davis, B.S.; Bowen, R.A.; Bunning, M.L. Experimental Infection of North American Birds with the New York 1999 Strain of West Nile Virus. *Emerg. Infect. Dis.* **2003**, *9*, 311. [CrossRef]
47. Eidson, M.; Miller, J.; Kramer, L.; Cherry, B.; Hagiwara, Y. Dead Crow Densities and Human Cases of West Nile Virus, New York State, 2000. *Emerg. Infect. Dis.* **2001**, *7*, 662–664. [CrossRef]
48. Soverow, J.E.; Wellenius, G.A.; Fisman, D.N.; Mittleman, M.A. Infectious Disease in a Warming World: How Weather Influenced West Nile Virus in the United States (2001–2005). *Environ. Health Perspect.* **2009**, *117*, 1049–1052. [CrossRef]
49. Mostashari, F.; Bunning, M.L.; Kitsutani, P.T.; Singer, D.A.; Nash, D.; Cooper, M.J.; Katz, N.; Liljebjelke, K.A.; Biggerstaff, B.J.; Fine, A.D.; et al. Epidemic West Nile Encephalitis, New York, 1999: Results of a Household-Based Seroepidemiological Survey. *Lancet* **2001**, *358*, 261–264. [CrossRef]
50. O'Leary, D.R.; Marfin, A.A.; Montgomery, S.P.; Kipp, A.M.; Lehman, J.A.; Biggerstaff, B.J.; Elko, V.L.; Collins, P.D.; Jones, J.E.; Campbell, G.L. The Epidemic of West Nile Virus in the United States, 2002. *Vector Borne Zoonotic Dis.* **2004**, *4*, 61–70. [CrossRef]
51. Sejvar, J.J. Clinical Manifestations and Outcomes of West Nile Virus Infection. *Viruses* **2014**, *6*, 606–623. [CrossRef]
52. Stufano, A.; Schino, V.; Sacino, G.; Ravallese, R.; Ravallese, R.; De Benedictis, L.; Morea, A.; Iatta, R.; Giannecchini, S.; Stincarelli, M.A.; et al. West Nile Virus Seroprevalence Among Outdoor Workers in Southern Italy: Unveiling Occupational Risks and Public Health Implications. *Viruses* **2025**, *17*, 310. [CrossRef] [PubMed]
53. Sattler, T.; Benka, B.; Zimpernik, I.; Pürrer, S.; Waldner, K.; Duscher, G.G.; Kuffer-Rosewick, A.; Fertey, J.; Ulbert, S.; Schmoll, F. Retrospective Cross-Sectional Study of Occupational Infection Risk with Zoonotic Pathogens in Austrian Veterinary Practitioners in the Year 2022. *Vet. Med. Sci.* **2025**, *11*, e70485. [CrossRef]
54. Murray, K.O.; Garcia, M.N.; Rahbar, M.H.; Martinez, D.; Khuwaja, S.A.; Arafat, R.R.; Rossmann, S. Survival Analysis, Long-Term Outcomes, and Percentage of Recovery up to 8 Years Post-Infection among the Houston West Nile Virus Cohort. *PLoS ONE* **2014**, *9*, e102953. [CrossRef] [PubMed]
55. Leis, A.A.; Stokic, D.S. Neuromuscular Manifestations of West Nile Virus Infection. *Front. Neurol.* **2012**, *3*, 37. [CrossRef]
56. Shrestha, B.; Diamond, M.S. Role of CD8+ T Cells in Control of West Nile Virus Infection. *J. Virol.* **2004**, *78*, 8312–8321. [CrossRef]
57. Klein, R.S.; Hunter, C.A. Protective and Pathological Immunity during Central Nervous System Infections. *Immunity* **2017**, *46*, 891–909. [CrossRef]
58. Hyde, J.L.; Diamond, M.S. Innate Immune Restriction and Antagonism of Viral RNA Lacking 2′-O Methylation. *Virology* **2015**, *479–480*, 66–74. [CrossRef]
59. Shrestha, B.; Samuel, M.A.; Diamond, M.S. CD8+ T Cells Require Perforin To Clear West Nile Virus from Infected Neurons. *J. Virol.* **2006**, *80*, 119–129. [CrossRef]
60. Wang, T.; Town, T.; Alexopoulou, L.; Anderson, J.F.; Fikrig, E.; Flavell, R.A. Toll-like Receptor 3 Mediates West Nile Virus Entry into the Brain Causing Lethal Encephalitis. *Nat. Med.* **2004**, *10*, 1366–1373. [CrossRef] [PubMed]

61. Best, S.M. The Many Faces of the Flavivirus NS5 Protein in Antagonism of Type I Interferon Signaling. *J. Virol.* **2017**, *91*, e01970-16. [CrossRef] [PubMed]
62. Samuel, M.A.; Diamond, M.S. Alpha/Beta Interferon Protects against Lethal West Nile Virus Infection by Restricting Cellular Tropism and Enhancing Neuronal Survival. *J. Virol.* **2005**, *79*, 13350–13361. [CrossRef] [PubMed]
63. Diamond, M.S.; Shrestha, B.; Mehlhop, E.; Sitati, E.; Engle, M. Innate and Adaptive Immune Responses Determine Protection against Disseminated Infection by West Nile Encephalitis Virus. *Viral Immunol.* **2003**, *16*, 259–278. [CrossRef]
64. Oliphant, T.; Engle, M.; Nybakken, G.E.; Doane, C.; Johnson, S.; Huang, L.; Gorlatov, S.; Mehlhop, E.; Marri, A.; Chung, K.M.; et al. Development of a Humanized Monoclonal Antibody with Therapeutic Potential against West Nile Virus. *Nat. Med.* **2005**, *11*, 522–530. [CrossRef]
65. Zhang, S.; Vogt, M.R.; Oliphant, T.; Engle, M.; Bovshik, E.I.; Diamond, M.S.; Beasley, D.W.C. The Development of Resistance to Passive Therapy by a Potently Neutralizing Humanized West Nile Virus Monoclonal Antibody. *J. Infect. Dis.* **2009**, *200*, 202–205. [CrossRef]
66. Sitati, E.M.; Diamond, M.S. CD4+ T-Cell Responses Are Required for Clearance of West Nile Virus from the Central Nervous System. *J. Virol.* **2006**, *80*, 12060–12069. [CrossRef]
67. Liu, W.J.; Wang, X.J.; Mokhonov, V.V.; Shi, P.-Y.; Randall, R.; Khromykh, A.A. Inhibition of Interferon Signaling by the New York 99 Strain and Kunjin Subtype of West Nile Virus Involves Blockage of STAT1 and STAT2 Activation by Nonstructural Proteins. *J. Virol.* **2005**, *79*, 1934–1942. [CrossRef]
68. Keller, B.C.; Fredericksen, B.L.; Samuel, M.A.; Mock, R.E.; Mason, P.W.; Diamond, M.S.; Gale, M. Resistance to Alpha/Beta Interferon Is a Determinant of West Nile Virus Replication Fitness and Virulence. *J. Virol.* **2006**, *80*, 9424–9434. [CrossRef]
69. Pan, Y.; Cai, W.; Cheng, A.; Wang, M.; Yin, Z.; Jia, R. Flaviviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines. *Front. Immunol.* **2022**, *13*, 829433. [CrossRef] [PubMed]
70. Anderson, J.F.; Rahal, J.J. Efficacy of Interferon α-2b and Ribavirin against West Nile Virus In Vitro. *Emerg. Infect. Dis.* **2002**, *8*, 107. [CrossRef] [PubMed]
71. CDC West Nile Virus Disease Therapeutics: Review of the Literature. Available online: https://www.cdc.gov/west-nile-virus/hcp/treatment-prevention/therapeutics-review.html (accessed on 12 August 2025).
72. Prince, H.E.; Tobler, L.H.; Yeh, C.; Gefter, N.; Custer, B.; Busch, M.P. Persistence of West Nile Virus-Specific Antibodies in Viremic Blood Donors. *Clin. Vaccine Immunol.* **2007**, *14*, 1228–1230. [CrossRef] [PubMed]
73. Roehrig, J.T.; Nash, D.; Maldin, B.; Labowitz, A.; Martin, D.A.; Lanciotti, R.S.; Campbell, G.L. Persistence of Virus-Reactive Serum Immunoglobulin m Antibody in Confirmed West Nile Virus Encephalitis Cases. *Emerg. Infect. Dis.* **2003**, *9*, 376–379. [CrossRef] [PubMed]
74. Martin, D.A.; Biggerstaff, B.J.; Allen, B.; Johnson, A.J.; Lanciotti, R.S.; Roehrig, J.T. Use of Immunoglobulin M Cross-Reactions in Differential Diagnosis of Human Flaviviral Encephalitis Infections in the United States. *Clin. Diagn. Lab. Immunol.* **2002**, *9*, 544–549. [CrossRef] [PubMed]
75. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections—National Library of Medicine Institution. Available online: https://catalog.nlm.nih.gov/discovery/fulldisplay/alma995260023406676/01NLM_INST:01NLM_INST (accessed on 18 August 2025).
76. Vilibic-Cavlek, T.; Bogdanic, M.; Savic, V.; Hruskar, Z.; Barbic, L.; Stevanovic, V.; Antolasic, L.; Milasincic, L.; Sabadi, D.; Miletic, G.; et al. Diagnosis of West Nile Virus Infections: Evaluation of Different Laboratory Methods. *World J. Virol.* **2024**, *13*, 95986. [CrossRef]
77. Lustig, Y.; Mannasse, B.; Koren, R.; Katz-Likvornik, S.; Hindiyeh, M.; Mandelboim, M.; Dovrat, S.; Sofer, D.; Mendelson, E. Superiority of West Nile Virus RNA Detection in Whole Blood for Diagnosis of Acute Infection. *J. Clin. Microbiol.* **2016**, *54*, 2294–2297. [CrossRef] [PubMed]
78. Anastasiadou, A.; Kakoulidis, I.; Butel, D.; Kehagia, E.; Papa, A. Follow-up Study of Greek Patients with West Nile Virus Neuroinvasive Disease. *Int. J. Infect. Dis.* **2013**, *17*, e494–e497. [CrossRef] [PubMed]
79. Carrasco, L.; Utrilla, M.J.; Fuentes-Romero, B.; Fernandez-Novo, A.; Martin-Maldonado, B. West Nile Virus: An Update Focusing on Southern Europe. *Microorganisms* **2024**, *12*, 2623. [CrossRef] [PubMed]
80. Shimoni, Z.; Niven, M.J.; Pitlick, S.; Bulvik, S. Treatment of West Nile Virus Encephalitis with Intravenous Immunoglobulin. *Emerg. Infect. Dis.* **2001**, *7*, 759. [CrossRef]
81. Haley, M.; Retter, A.S.; Fowler, D.; Gea-Banacloche, J.; O'Grady, N.P. The Role for Intravenous Immunoglobulin in the Treatment of West Nile Virus Encephalitis. *Clin. Infect. Dis.* **2003**, *37*, e88–e90. [CrossRef]
82. Hamdan, A.; Green, P.; Mendelson, E.; Kramer, M.R.; Pitlik, S.; Weinberger, M. Possible Benefit of Intravenous Immunoglobulin Therapy in a Lung Transplant Recipient with West Nile Virus Encephalitis. *Transpl. Infect. Dis.* **2002**, *4*, 160–162. [CrossRef]
83. Kalil, A.C.; Devetten, M.P.; Singh, S.; Lesiak, B.; Poage, D.P.; Bargenquast, K.; Fayad, P.; Freifeld, A.G. Use of Interferon-Alpha in Patients with West Nile Encephalitis: Report of 2 Cases. *Clin. Infect. Dis.* **2005**, *40*, 764–766. [CrossRef]

84. Leyssen, P.; Drosten, C.; Paning, M.; Charlier, N.; Paeshuyse, J.; De Clercq, E.; Neyts, J. Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice. *Antimicrob. Agents Chemother.* **2003**, *47*, 777–782. [CrossRef]
85. Leyssen, P.; Balzarini, J.; De Clercq, E.; Neyts, J. The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase. *J. Virol.* **2005**, *79*, 1943–1947. [CrossRef]
86. Moscatt, V.; Marino, A.; Ceccarelli, M.; Cosentino, F.; Zagami, A.; Celesia, B.M.; Nunnari, G.; Cacopardo, B. Possible Role of Low Dose Dexamethasone Administration in Listeria Monocytogenes Meningoencephalitis: A Case Series. *Biomed. Rep.* **2022**, *17*, 73. [CrossRef]
87. Kneen, R.; Michael, B.D.; Menson, E.; Mehta, B.; Easton, A.; Hemingway, C.; Klapper, P.E.; Vincent, A.; Lim, M.; Carrol, E.; et al. Management of Suspected Viral Encephalitis in Children—Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group National Guidelines. *J. Infect.* **2012**, *64*, 449–477. [CrossRef]
88. Tunkel, A.R.; Glaser, C.A.; Bloch, K.C.; Sejvar, J.J.; Marra, C.M.; Roos, K.L.; Hartman, B.J.; Kaplan, S.L.; Scheld, W.M.; Whitley, R.J. The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America. *Clin. Infect. Dis.* **2008**, *47*, 303–327. [CrossRef] [PubMed]
89. Hodzic, E.; Hasbun, R.; Granillo, A.; Tröscher, A.R.; Wagner, H.; von Oertzen, T.J.; Wagner, J.N. Steroids for the Treatment of Viral Encephalitis: A Systematic Literature Review and Meta-Analysis. *J. Neurol.* **2023**, *270*, 3603–3615. [CrossRef]
90. Beigel, J.H.; Nordstrom, J.L.; Pillemer, S.R.; Roncal, C.; Goldwater, D.R.; Li, H.; Holland, P.C.; Johnson, S.; Stein, K.; Koenig, S. Safety and Pharmacokinetics of Single Intravenous Dose of MGAWN1, a Novel Monoclonal Antibody to West Nile Virus. *Antimicrob. Agents Chemother.* **2010**, *54*, 2431–2436. [CrossRef]
91. Campbell, G.L.; Marfin, A.A.; Lanciotti, R.S.; Gubler, D.J. West Nile Virus. *Lancet Infect. Dis.* **2002**, *2*, 519–529. [CrossRef] [PubMed]
92. van den Hurk, A.F.; Ritchie, S.A.; Mackenzie, J.S. Ecology and Geographical Expansion of Japanese Encephalitis Virus. *Annu. Rev. Entomol.* **2009**, *54*, 17–35. [CrossRef] [PubMed]
93. Reisen, W.K. Landscape Epidemiology of Vector-Borne Diseases. *Annu. Rev. Entomol.* **2010**, *55*, 461–483. [CrossRef]
94. Rose, R.I. Pesticides and Public Health: Integrated Methods of Mosquito Management. *Emerg. Infect. Dis.* **2001**, *7*, 17–23. [CrossRef]
95. Goddard, L.B.; Roth, A.E.; Reisen, W.K.; Scott, T.W. Vector Competence of California Mosquitoes for West Nile Virus. *Emerg. Infect. Dis.* **2002**, *8*, 1385–1391. [CrossRef]
96. Carney, R.M.; Ahearn, S.C.; McConchie, A.; Glaser, C.; Jean, C.; Barker, C.; Park, B.; Padgett, K.; Parker, E.; Aquino, E.; et al. Early Warning System for West Nile Virus Risk Areas, California, USA. *Emerg. Infect. Dis.* **2011**, *17*, 1445–1454. [CrossRef]
97. Bonds, J.A.S. Ultra-Low-Volume Space Sprays in Mosquito Control: A Critical Review. *Med. Vet. Entomol.* **2012**, *26*, 121–130. [CrossRef]
98. Fradin, M.S.; Day, J.F. Comparative Efficacy of Insect Repellents against Mosquito Bites. *N. Engl. J. Med.* **2002**, *347*, 13–18. [CrossRef]
99. Barnard, D.R.; Xue, R.-D. Laboratory Evaluation of Mosquito Repellents against Aedes Albopictus, Culex Nigripalpus, and Ochierotatus Triseriatus (Diptera: Culicidae). *J. Med. Entomol.* **2004**, *41*, 726–730. [CrossRef]
100. Fonzo, M.; Bertoncello, C.; Tudor, L.; Miccolis, L.; Serpentino, M.; Petta, D.; Amoruso, I.; Baldovin, T.; Trevisan, A. Do We Protect Ourselves against West Nile Virus? A Systematic Review on Knowledge, Attitudes, and Practices and Their Determinants. *J. Infect. Public Health* **2024**, *17*, 868–880. [CrossRef] [PubMed]
101. Zou, S.; Foster, G.A.; Dodd, R.Y.; Petersen, L.R.; Stramer, S.L. West Nile Fever Characteristics among Viremic Persons Identified through Blood Donor Screening. *J. Infect. Dis.* **2010**, *202*, 1354–1361. [CrossRef] [PubMed]
102. Pozzetto, B.; Grard, G.; Durand, G.; Paty, M.-C.; Gallian, P.; Lucas-Samuel, S.; Diéterlé, S.; Fromage, M.; Durand, M.; Lepelletier, D.; et al. Arboviral Risk Associated with Solid Organ and Hematopoietic Stem Cell Grafts: The Prophylactic Answers Proposed by the French High Council of Public Health in a National Context. *Viruses* **2023**, *15*, 1783. [CrossRef]
103. Abbas, I.; Ahmed, F.; Muqaddas, H.; Alberti, A.; Varcasia, A.; Sedda, L. Epidemiology and Surveillance of West Nile Virus in the Mediterranean Basin during 2010–2023: A Systematic Review. *Curr. Res. Parasitol. Vector-Borne Dis.* **2025**, *7*, 100277. [CrossRef]
104. Nash, D.; Mostashari, F.; Fine, A.; Miller, J.; O'Leary, D.; Murray, K.; Huang, A.; Rosenberg, A.; Greenberg, A.; Sherman, M.; et al. The Outbreak of West Nile Virus Infection in the New York City Area in 1999. *N. Engl. J. Med.* **2001**, *344*, 1807–1814. [CrossRef]
105. Cendejas, P.M.; Goodman, A.G. Vaccination and Control Methods of West Nile Virus Infection in Equids and Humans. *Vaccines* **2024**, *12*, 485. [CrossRef] [PubMed]
106. Monath, T.P. Prospects for Development of a Vaccine against the West Nile Virus. *Ann. N. Y. Acad. Sci.* **2001**, *951*, 1–12. [CrossRef]
107. Ledgerwood, J.E.; Pierson, T.C.; Hubka, S.A.; Desai, N.; Rucker, S.; Gordon, I.J.; Enama, M.E.; Nelson, S.; Nason, M.; Gu, W.; et al. A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. *J. Infect. Dis.* **2011**, *203*, 1396–1404. [CrossRef] [PubMed]

108. Guirakhoo, F.; Pugachev, K.; Zhang, Z.; Myers, G.; Levenbook, I.; Draper, K.; Lang, J.; Ocran, S.; Mitchell, F.; Parsons, M.; et al. Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates. *J. Virol.* **2004**, *78*, 4761–4775. [CrossRef]
109. Dayan, G.H.; Pugachev, K.; Bevilacqua, J.; Lang, J.; Monath, T.P. Preclinical and Clinical Development of a YFV 17 D-Based Chimeric Vaccine against West Nile Virus. *Viruses* **2013**, *5*, 3048–3070. [CrossRef]
110. NCT06745921: Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults. Cochrane Library: Chichester, UK, 2025. Available online: https://clinicaltrials.gov/study/NCT06745921 (accessed on 31 October 2025).
111. Beasley, D.W.C.; Barrett, A.D.T.; Tesh, R.B. Resurgence of West Nile Neurologic Disease in the United States in 2012: What Happened? What Needs to Be Done? *Antivir. Res.* **2013**, *99*, 1–5. [CrossRef]
112. Vuitika, L.; Prates-Syed, W.A.; Silva, J.D.Q.; Crema, K.P.; Côrtes, N.; Lira, A.; Lima, J.B.M.; Camara, N.O.S.; Schimke, L.F.; Cabral-Marques, O.; et al. Vaccines against Emerging and Neglected Infectious Diseases: An Overview. *Vaccines* **2022**, *10*, 1385. [CrossRef]
113. Thomas, S.J.; Yoon, I.-K. A Review of Dengvaxia®: Development to Deployment. *Hum. Vaccin. Immunother.* **2019**, *15*, 2295–2314. [CrossRef]
114. Boccalini, S. Value of Vaccinations: A Fundamental Public Health Priority to Be Fully Evaluated. *Vaccines* **2025**, *13*, 479. [CrossRef] [PubMed]
115. Halstead, S.B. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. *Microbiol. Spectr.* **2014**, *2*, 249–271. [CrossRef]
116. Bardina, S.V.; Bunduc, P.; Tripathi, S.; Duehr, J.; Frere, J.J.; Brown, J.A.; Nachbagauer, R.; Foster, G.A.; Krysztof, D.; Tortorella, D.; et al. Enhancement of Zika Virus Pathogenesis by Preexisting Antiflavivirus Immunity. *Science* **2017**, *356*, 175–180. [CrossRef] [PubMed]
117. Eyal, N.; Lipsitch, M.; Smith, P.G. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. *J. Infect. Dis.* **2020**, *221*, 1752–1756. [CrossRef]
118. Screaton, G.; Mongkolsapaya, J.; Yacoub, S.; Roberts, C. New Insights into the Immunopathology and Control of Dengue Virus Infection. *Nat. Rev. Immunol.* **2015**, *15*, 745–759. [CrossRef]
119. Lim, S.P.; Shi, P.-Y. West Nile Virus Drug Discovery. *Viruses* **2013**, *5*, 2977–3006. [CrossRef] [PubMed]
120. Sinigaglia, A.; Peta, E.; Riccetti, S.; Barzon, L. New Avenues for Therapeutic Discovery against West Nile Virus. *Expert. Opin. Drug Discov.* **2020**, *15*, 333–348. [CrossRef]
121. Bollati, M.; Alvarez, K.; Assenberg, R.; Baronti, C.; Canard, B.; Cook, S.; Coutard, B.; Decroly, E.; de Lamballerie, X.; Gould, E.A.; et al. Structure and Functionality in Flavivirus NS-Proteins: Perspectives for Drug Design. *Antivir. Res.* **2010**, *87*, 125–148. [CrossRef] [PubMed]
122. Saeedi, B.J.; Geiss, B.J. Regulation of Flavivirus RNA Synthesis and Capping. *Wiley Interdiscip. Rev. RNA* **2013**, *4*, 723–735. [CrossRef] [PubMed]
123. Li, S.; Li, H.; Lian, R.; Xie, J.; Feng, R. New Perspective of Small-Molecule Antiviral Drugs Development for RNA Viruses. *Virology* **2024**, *594*, 110042. [CrossRef]
124. Barker, C.M.; Niu, T.; Reisen, W.K.; Hartley, D.M. Data-Driven Modeling to Assess Receptivity for Rift Valley Fever Virus. *PLoS Negl. Trop. Dis.* **2013**, *7*, e2515. [CrossRef]
125. Shaman, J.; Day, J.F.; Stieglitz, M. Drought-Induced Amplification and Epidemic Transmission of West Nile Virus in Southern Florida. *J. Med. Entomol.* **2005**, *42*, 134–141. [CrossRef]
126. Farooq, Z.; Rocklöv, J.; Wallin, J.; Abiri, N.; Sewe, M.O.; Sjödin, H.; Semenza, J.C. Artificial Intelligence to Predict West Nile Virus Outbreaks with Eco-Climatic Drivers. *Lancet Reg. Health–Eur.* **2022**, *17*, 100370. [CrossRef]
127. Keyel, A.C.; Timm, O.E.; Backenson, P.B.; Prussing, C.; Quinones, S.; McDonough, K.A.; Vuille, M.; Conn, J.E.; Armstrong, P.M.; Andreadis, T.G.; et al. Seasonal Temperatures and Hydrological Conditions Improve the Prediction of West Nile Virus Infection Rates in Culex Mosquitoes and Human Case Counts in New York and Connecticut. *PLoS ONE* **2019**, *14*, e0217854. [CrossRef]
128. Samuel, M.A.; Diamond, M.S. Pathogenesis of West Nile Virus Infection: A Balance between Virulence, Innate and Adaptive Immunity, and Viral Evasion. *J. Virol.* **2006**, *80*, 9349–9360. [CrossRef]
129. Sejvar, J.J.; Curns, A.T.; Welburg, L.; Jones, J.F.; Lundgren, L.M.; Capuron, L.; Pape, J.; Reeves, W.C.; Campbel, G.L. Neurocognitive and Functional Outcomes in Persons Recovering from West Nile Virus Illness. *J. Neuropsychol.* **2008**, *2*, 477–499. [CrossRef]
130. Carson, P.J.; Konewko, P.; Wold, K.S.; Mariani, P.; Goli, S.; Bergloff, P.; Crosby, R.D. Long-Term Clinical and Neuropsychological Outcomes of West Nile Virus Infection. *Clin. Infect. Dis.* **2006**, *43*, 723–730. [CrossRef]
131. May, F.J.; Davis, C.T.; Tesh, R.B.; Barrett, A.D.T. Phylogeography of West Nile Virus: From the Cradle of Evolution in Africa to Eurasia, Australia, and the Americas. *J. Virol.* **2011**, *85*, 2964–2974. [CrossRef] [PubMed]
132. Mann, B.R.; McMullen, A.R.; Swetnam, D.M.; Barrett, A.D.T. Molecular Epidemiology and Evolution of West Nile Virus in North America. *Int. J. Environ. Res. Public Health* **2013**, *10*, 5111–5129. [CrossRef]
133. Paz, S. Climate Change Impacts on West Nile Virus Transmission in a Global Context. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **2015**, *370*, 20130561. [CrossRef] [PubMed]

134. Rochlin, I.; Faraji, A.; Healy, K.; Andreadis, T.G. West Nile Virus Mosquito Vectors in North America. *J. Med. Entomol.* **2019**, *56*, 1475–1490. [CrossRef]
135. Kilpatrick, A.M.; Randolph, S.E. Drivers, Dynamics, and Control of Emerging Vector-Borne Zoonotic Diseases. *Lancet* **2012**, *380*, 1946–1955. [CrossRef] [PubMed]